

# Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age

Tommaso Ballarini, PhD, Debora Melo van Lent, PhD, Julia Brunner, MSc, Alina Schröder, MSc, Steffen Wolfgruber, PhD, Slawek Altenstein, Dipl-Psych, Frederic Brosseron, PhD, Katharina Buerger, MD, Peter Dechent, PhD, Laura Dobisch, MSc, Emrah Düzel, MD, Birgit Ertl-Wagner, MD, Klaus Fließbach, MD, Silka Dawn Freiesleben, MSc, Ingo Frommann, Dipl-Psych, Wenzel Glanz, MD, Dietmar Hauser, Dipl-Psych, John Dylan Haynes, PhD, Michael T. Heneka, MD, Daniel Janowitz, MD, Ingo Kilimann, MD, Christoph Laske, MD, Franziska Maier, MD, Coraline Danielle Metzger, MD, Matthias H. Munk, MD, Robert Perneczky, MD, Oliver Peters, MD, Josef Priller, MD, Alfredo Ramirez, MD, Boris-Stephan Rauchmann, MD, Nina Roy, PhD, Klaus Scheffler, PhD, Anja Schneider, MD, Annika Spottke, MD, Eike Jakob Spruth, MD, Stefan J. Teipel, MD, Ruth Vukovich, MD, Jens Wiltfang, MD, Frank Jessen, MD, and Michael Wagner, PhD, on behalf of the DELCODE Study Group

## Correspondence

Dr. Ballarini  
tommaso.ballarini@dzne.de

Neurology® 2021;96:e2920-e2932. doi:10.1212/WNL.00000000000012067

## Abstract

### Objective

To determine whether following a Mediterranean-like diet (MeDi) relates to cognitive functions and in vivo biomarkers for Alzheimer disease (AD), we analyzed cross-sectional data from the German DZNE-Longitudinal Cognitive Impairment and Dementia Study.

### Method

The sample ( $n = 512$ , mean age  $69.5 \pm 5.9$  years) included 169 cognitively normal participants and individuals at higher AD risk (53 with relatives with AD, 209 with subjective cognitive decline, and 81 with mild cognitive impairment). We defined MeDi adherence according to the food frequency questionnaire. Brain volume outcomes were generated via voxel-based morphometry on T1-MRI, and cognitive performance was assessed with an extensive neuropsychological battery. AD-related biomarkers ( $\beta$ -amyloid<sub>42/40</sub> [ $A\beta_{42/40}$ ] ratio, phosphorylated tau 181 [pTau181]) in CSF were assessed in  $n = 226$  individuals. We analyzed the associations between MeDi and outcomes with linear regression models controlling for several covariates. In addition, we applied hypothesis-driven mediation and moderation analysis.

### Results

Higher MeDi adherence related to larger mediotemporal gray matter volume ( $p < 0.05$  family-wise error corrected), better memory ( $\beta \pm SE = 0.03 \pm 0.02$ ;  $p = 0.038$ ), and less amyloid ( $A\beta_{42/40}$  ratio,  $\beta \pm SE = 0.003 \pm 0.001$ ;  $p = 0.008$ ) and pTau181 ( $\beta \pm SE = -1.96 \pm 0.68$ ;  $p = 0.004$ ) pathology. Mediotemporal volume mediated the association between MeDi and memory (40% indirect mediation). Finally, MeDi favorably moderated the associations among  $A\beta_{42/40}$  ratio, pTau181, and mediotemporal atrophy. Results were consistent correcting for APOE- $\epsilon 4$  status.

## MORE ONLINE

### CME Course

NPub.org/cmelist

From the German Center for Neurodegenerative Diseases (DZNE) (T.B., D.M.v.L., J.B., A.Schröder, S.W., F.B., K.F., I.F., M.T.H., N.R., A. Schneider, A. Spottke, F.J., M.W.), Bonn, Venusberg-Campus 1, Bonn, Germany; University of Texas Health Science Center at San Antonio (D.M.v.L.); Department of Neurodegeneration and Geriatric Psychiatry (S.W., F.B., K.F., M.T.H., A. Schneider, M.W.), University Hospital Bonn, Venusberg-Campus 1; German Center for Neurodegenerative Diseases (DZNE) (S.A., O.P., J.P., E.J.S.); Department of Psychiatry and Psychotherapy (S.A., J.P., E.J.S.), Charité, Charitéplatz 1, Berlin; German Center for Neurodegenerative Diseases (DZNE, Munich) (K.B., R.P.); Institute for Stroke and Dementia Research (ISD) (K.B.), University Hospital, LMU Munich; MR-Research in Neurology and Psychiatry (P.D.), Georg-August University Göttingen; German Center for Neurodegenerative Diseases (DZNE) (L.D., E.D., W.G., C.D.M.); Institute of Cognitive Neurology and Dementia Research (IKND) (L.D., E.D., C.D.M.), Otto-von-Guericke University, Magdeburg; Institute for Clinical Radiology (B.E.-W.), Ludwig-Maximilians-University, Munich; Charité Universitätsmedizin Berlin (S.D.F., D.H., O.P.), Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin; Bernstein Center for Computational Neuroscience (J.D.H.), Charité Universitätsmedizin, Berlin; Institute for Stroke and Dementia Research (ISD) (D.J.), University Hospital, LMU Munich; German Center for Neurodegenerative Diseases (DZNE) (I.K., S.J.T.); Department of Psychosomatic Medicine (I.K., S.J.T.), Rostock University Medical Center; German Center for Neurodegenerative Diseases (DZNE) (C.L., M.H.M.); Section for Dementia Research (C.L., M.H.M.), Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen; Department of Psychiatry (F.M., A.R., F.J.), University of Cologne, Medical Faculty; Department of Psychiatry and Psychotherapy (R.P., B.R.), University Hospital, LMU Munich; Munich Cluster for Systems Neurology (SyNergy) (R.P.) Munich, Germany; Ageing Epidemiology Research Unit (AGE) (R.P.), School of Public Health, Imperial College London, UK; Department for Biomedical Magnetic Resonance (K.S.), University of Tübingen; Department of Neurology (A. Spottke), University of Bonn, Venusberg-Campus 1; Department of Psychiatry and Psychotherapy (R.V., J.W.), University Medical Center Goettingen, University of Goettingen; German Center for Neurodegenerative Diseases (DZNE) (J.W.), Goettingen, Germany; Neurosciences and Signaling Group (J.W.), Institute of Biomedicine (iBiMED), Department of Medical Sciences (J.W.), University of Aveiro, Portugal; and Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD) (F.J.), University of Cologne, Germany.

Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Coinvestigators are listed at links.lww.com/WNL/B405.

## Glossary

A $\beta$  =  $\beta$ -amyloid; AD = Alzheimer disease; BMI = body mass index; CAT12 = Computational Anatomy Toolbox; CERAD = Consortium to Establish a Registry for Alzheimer's Disease; CI = confidence interval; DELCODE = DZNE-Longitudinal Cognitive Impairment and Dementia Study; EPIC = European Prospective Investigation of Cancer; *est* = effect estimate; FFQ = food frequency questionnaire; FWE = family-wise error; MCI = mild cognitive impairment; MeDi = Mediterranean diet; PREDIMED = Prevención con Dieta Mediterránea; pTau181 = phosphorylated tau 181; ROI = region of interest; SCD = subjective cognitive decline; SPM12 = Statistical Parametric Mapping.

## Conclusion

Our findings corroborate the view of MeDi as a protective factor against memory decline and mediotemporal atrophy. They suggest that these associations might be explained by a decrease of amyloidosis and tau pathology. Longitudinal and dietary intervention studies should further examine this conjecture and its treatment implications.

Healthy dietary patterns such as the Mediterranean diet (MeDi) might reduce the risk of dementia and cognitive decline.<sup>1-4</sup> Although contrasting findings have been reported as well,<sup>5,6</sup> encouraging results were provided by the Prevención con Dieta Mediterránea (PREDIMED) study, a randomized clinical trial in which a MeDi intervention was associated with both improved cognitive functioning<sup>7</sup> and reduced incident mild cognitive impairment (MCI).<sup>8</sup> Likewise, adherence to MeDi could diminish the conversion rate from MCI to dementia.<sup>9,10</sup>

At the biomarker level, MeDi has been associated with preserved cortical thickness and brain volume in middle-aged<sup>11,12</sup> and older individuals,<sup>13-15</sup> especially in brain regions associated with aging and Alzheimer disease (AD). Moreover, adherence to MeDi has been related to lower amyloid load studied with <sup>11</sup>C-Pittsburgh compound B-PET in cognitively unimpaired individuals,<sup>11,16,17</sup> while another study could not find such an association using <sup>18</sup>F-florbetaben-PET.<sup>18</sup> Furthermore, 1 study found an association in volunteers with subjective cognitive decline (SCD) or MCI between MeDi and lower FDDNP-PET, a compound measure of amyloid and tau pathology.<sup>19</sup> Two longitudinal studies reported better MeDi adherence to be associated with less amyloid accumulation over time.<sup>17,20</sup>

This initial evidence suggests that MeDi might reduce amyloid deposition since midlife with a probable downstream effect on neurodegeneration and cognition. We in addition hypothesized that MeDi is associated with tau levels and moderates the associations among amyloid, tau, and brain atrophy. Here, we examined these questions by leveraging a large cohort of older individuals at increased risk for AD.

## Methods

### Standard Protocol Approvals, Registrations, and Patient Consents

At each DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE) site, the local institutional review

boards approved the study protocol, and the ethics committees issued local ethics approval. DELCODE is registered at the German Clinical Trials Register (DRKS00007966; April 5, 2015). The study protocol followed the ethics principles for human experimentation in accordance with the Declaration of Helsinki. All participants in the study provided written informed consent.

### Participants

As of July 2020, the baseline of the German multicenter DELCODE includes 1,079 individuals. A complete overview of the study design, group definitions, and aims is provided in a previous paper.<sup>21</sup> Here, we selected 512 individuals (average  $\pm$  SD age 69.49  $\pm$  5.86 years, 270 female, self-reported sex) according to availability of both the detailed food frequency questionnaire (FFQ) and T1-weighted MRI. The sample was enriched for risk of AD in that it included individuals with SCD (*n* = 209, 41%) or amnesic MCI (*n* = 81, 16%) who were referrals to the participating memory clinics. Participants with SCD reported self-perceived cognitive decline with concerns while showing a preserved performance in all tests of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropsychological battery (above  $-1.5$  SDs compared to age-, sex-, and education-adjusted norms). Conversely, individuals with amnesic MCI performed below  $-1.5$  SDs on the delayed-recall trial of the CERAD word-list episodic memory tests. The clinical diagnoses were part of the clinical workup at each site (not of DELCODE itself) and conformed to published research criteria.<sup>22-24</sup> In addition, first-degree relatives of patients with AD (*n* = 53, 10%) and cognitively normal volunteers without increased risk for AD (*n* = 169, 33%) were recruited with an advertisement campaign in local newspapers. Both groups met the requirement for an unimpaired cognitive performance on the CERAD battery (as the SCD group).

Complete demographic information is reported in table 1 and stratified by clinical group in table e-2, doi.org/10.5061/dryad.6t1g1jwxg. A subsample of 226 participants in addition underwent lumbar puncture for assessment of AD-related

**Table 1** Demographic and Basic Clinical Characteristics (n = 512)

Variables	Mean	SD	Min	Max
Age, y	69.49	5.86	59	86
Education, y	14.57	2.91	8	20
MMSE score, range 0–30	29.10	1.30	18	30
CDR Sum of Boxes score, range 0–18	0.43	0.86	0	7.5
BMI, kg/m <sup>2a</sup>	25.76	3.83	16.00	47.00
Daily energy intake, kcal/d	2,298.95	743.26	765.10	4,954.60
Physical activity score (PASE) <sup>a</sup>	31.10	11.95	4.67	78.75
Mediterranean diet score, range 0–9	4.53	1.64	0	8
MEM score	0.31	0.7	−2.2	3.83
Frequencies (%)				
F/M, n (%)	270/242 (52.7/47.3)			
APOE ε4 carriers/noncarriers, n (%) <sup>a</sup>	143/358 (28.54/71.46)			
Cognitive status, n (%)				
Cognitively normal	431 (84.2%)			
MCI	81 (15.8%)			

Abbreviations: BMI = body mass index; CDR = Clinical Dementia Rating; Max = maximum; MCI = mild cognitive impairment; MEM = memory summary factor score; Min = minimum; MMSE = Mini-Mental State Examination; PASE = Physical Activity Scale for the Elderly.

<sup>a</sup> Incomplete data: 508 cases for BMI, 504 for CDR, 494 for PASE, and 501 for APOE ε4 status.

neuropathologic biomarkers in CSF. Comparing the groups with and without CSF information, we did not find differences in age, sex distribution, prevalence of APOE ε4, body mass index (BMI; kilocalories per day), level of physical activity (as measured with the Physical Activity Scale for the Elderly),<sup>25</sup> or MeDi score. However, individuals with CSF data available had a lower educational attainment, a higher prevalence of MCI, and accordingly a lower performance on the Mini-Mental State Examination (table e-1).

## MRI Acquisition

The acquisition of structural brain images was performed with 3T MRI scanners mounting 32-channel head array coils. A 3D T1-weighted magnetization prepared rapid gradient echo sequence was used, with an echo time of 4.37 milliseconds, repetition time of 2,500 milliseconds, inversion time of 1,100 milliseconds, and flip angle of 7°. All images had a 1-mm<sup>3</sup> isotropic nominal image resolution with a final image matrix of 256 × 256 × 192. Four different MRI scanners from Siemens (Siemens Healthcare, Erlangen, Germany) were used across centers: MAGNETOM TrioTim (n = 209), Verio (n = 163), Skyra (n = 110), and Prisma (n = 30). Image quality assessment is described in the supplements (doi.org/10.5061/dryad.6t1gljwxg).

## Cognitive Assessment

All study participants underwent an in-depth neuropsychological assessment to cover a broad spectrum of cognitive functioning.<sup>21</sup> Our analysis focused on 5 factor scores derived from a confirmatory factor analysis and capturing the cognitive performance in different domains: memory, language, executive functions, working memory, and visuospatial abilities. Rationale and methods for the definition of factor scores are described in a previous paper.<sup>26</sup> A list of the cognitive tests contributing to each cognitive domain is given in table e-3, doi.org/10.5061/dryad.6t1gljwxg/.

## Dietary Assessment and MeDi Score Definition

We administered the German adaptation of the semi-quantitative European Prospective Investigation of Cancer (EPIC) FFQ<sup>27</sup> (more details in supplements, doi.org/10.5061/dryad.6t1gljwxg/). Our sample of 512 participants did not include those who reported abnormal daily energy intake, defined as <500 or >5,000 kcal/d (n = 4) and individuals who did not answer more than 20% of the FFQ questions (n = 2).

We computed the a priori MeDi score on the basis of sex-specific medians from this study population. Briefly, food items from the EPIC-FFQ were clustered into 9 food categories. A score of 1 was assigned when the food intake for 1 participant was equal to or above the sex-specific median for 6 food categories typical of MeDi (fish, vegetables, fruits/nuts, legumes, cereals, and higher ratio of monounsaturated/saturated fats) or below the cutoff for foods nontypical of MeDi (meat, dairy products). For alcohol, a moderate consumption (10–50 g/d in men and 5–25 g/d in women) was considered beneficial and scored 1 point. The final MeDi score can span from 0 to 9, with higher values indicating higher adherence.<sup>28</sup> Table e-4 and figure e-3 (doi.org/10.5061/dryad.6t1gljwxg/) display each food category stratified by MeDi score (low, medium, high) and sex.

## CSF Sampling and Assessment


A subsample of 226 participants consented to undergo lumbar puncture. All procedures were guided by German Center for Neurodegenerative Diseases standard operating procedures (see supplementary Methods, doi.org/10.5061/dryad.6t1gljwxg/). We focused our analyses on phosphorylated tau 181 (pTau181), β-amyloid<sub>1–42</sub> (Aβ<sub>42</sub>), their ratio Aβ<sub>42</sub>/pTau181, and the Aβ<sub>42/40</sub> ratio to take into account individual differences in overall Aβ peptide concentrations.<sup>29</sup>

## Voxel-Based Morphometry Analysis

We applied voxel-based morphometry<sup>30</sup> to study the relationship between gray matter volume and MeDi. All analyses were performed with the Computational Anatomy Toolbox (CAT12) and Statistical Parametric Mapping (SPM12, Wellcome Trust Centre for Neuroimaging, University College London, UK) running on Matlab 2014b (The MathWorks, Inc., Natick, MA). All T1-MRI images were normalized to the Montreal Neurological Institute standard space and segmented into gray matter, white matter, and CSF



**Figure 1** Positive Association Between MeDi and Brain Volume



compartments. Modulation of preprocessed MRI images included both linear and nonlinear deformations (i.e., jacobian determinants) to account for contractions and expansions during image normalization. Image smoothing was applied with a 8-mm full width at half-maximum gaussian kernel. Total intracranial volume and total gray matter volume were extracted from CAT12 output.

The association between MeDi score and gray matter volume was investigated via application of the general linear model (1-sample  $t$  test in SPM12) with age, sex, total intracranial volume, and MRI scanner type entered as nuisance covariates. Heterogeneity in MRI devices was expressed with one-hot encoding for categorical data to avoid order effects. In addition, we reran the analysis correcting also for caloric intake, BMI, physical activity levels, and *APOE*  $\epsilon 4$  status. The model was first applied at the whole-brain level, without any a priori hypothesis, and then restricted to hypothesis-driven regions of interest (ROIs) in the mediotemporal lobe, which shows early changes in AD.<sup>31</sup> Anatomic ROIs were selected from the Automated Anatomical Labeling atlas using the Wake Forest University Pickatlas tool for SPM (bilateral hippocampi and parahippocampal gyri). Of note, the entorhinal cortex is included in the parahippocampal gyrus ROI as defined in the Automated Anatomical Labeling atlas (figure e-4, [doi.org/10.5061/dryad.6t1g1jwxg/](https://doi.org/10.5061/dryad.6t1g1jwxg/)). Correction for multiple comparisons was performed with the nonparametric threshold free cluster enhancement approach implemented in SPM ([neuro.uni-jena.de/tfce/](https://neuro.uni-jena.de/tfce/)). We used the threshold free cluster enhancement technique with 5,000 permutations, weighting parameters for cluster extent  $E = 0.6$  and height  $H = 2$  and a significance level of  $p < 0.05$  (family-wise error [FWE] corrected).

### Statistical Analysis on CSF Variables and Cognitive Factors

We assessed the associations between MeDi and cognition or CSF variables with linear regression models adjusted for age,


sex, and education. The analysis was repeated including supplementary covariates to control for potential confounding effects from BMI, caloric intake, and physical activity, as well as for *APOE*  $\epsilon 4$ . Outliers identified on CSF variables were removed from the analysis, leading to the exclusion of 12 individuals who had values at 1.5 multiplied by the interquartile range below or above the 25th or the 75th percentile, respectively. Figure e-2, [doi.org/10.5061/dryad.6t1g1jwxg/](https://doi.org/10.5061/dryad.6t1g1jwxg/), displays the distributions of CSF variables. We repeated the analysis without outlier exclusion (applying log transformation to pTau181) and with robust linear regression, which is less sensitive to outliers. Finally, all linear models were corrected for the time distance between baseline visit (when biomarkers and cognitive assessment took place) and FFQ questionnaire (mean  $\pm$  SD 41.5  $\pm$  43.17 weeks, median 51.7 weeks).

### Mediation Analysis

We created hypothesis-driven models and tested them with mediation and moderated mediation analysis. All models were created with processR and estimated with the lavaan package (version 0.6-5, [lavaan.ugent.be/](https://lavaan.ugent.be/)) in R version 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria).

The aim of model 1 was to investigate the interplay among MeDi, brain volume, and memory function. Specifically, we hypothesized that the brain changes observed in the bilateral hippocampi and parahippocampal regions mediate the association between MeDi and memory identified in the regression analyses (figure 2). The model included all the 512 individuals in the study. Gray matter values were extracted from the significant cluster from the ROI-based analysis using MarsBaR toolbox for SPM. To assess the specificity of the mediation effect for mediotemporal regions, we replicated a similar mediation model using total gray matter volume as mediator. A parameter to model the indirect effects of MeDi on memory via brain measures was included.

**Figure 2** Graphical Display of Mediation and Moderated Mediation Models



Names of the paths and associated regression estimates are reported. Solid lines represent significant paths according to confidence intervals generated with bias corrected bootstrap with 10,000 replicates. Dashed lines mark nonsignificant regression paths. For models 2.1 and 2.2, in addition to the statistical models, the conceptual models are shown in the upper right corners, and simple slopes representing the interactions effects are shown below. A complete overview of direct and indirect effects is reported in table 4. Aβ42/40 = ratio between β-amyloid42 and β-amyloid40; MeDi = Mediterranean diet; MEM = memory summary factor score; pTau = phosphorylated tau; rGMV = regional gray matter volume in bilateral hippocampi and parahippocampi.

We then designed additional models to disentangle the moderation effect of MeDi on the associations between Aβ42/40 ratio and pTau181 and brain volume in medi-otemporal regions. In particular, we adopted the theoretical framework of the amyloid cascade hypothesis according to which amyloidosis is the earliest upstream pathologic event that leads to tau phosphorylation and finally to brain atrophy.<sup>32</sup> The following models were therefore performed on the subsample with CSF information. The rationale for these

models is that MeDi adherence might sustain brain maintenance, thus reducing the development of disease-related brain changes and pathology.<sup>33</sup> In particular, we expected that MeDi moderates the paths connecting neuropathology and brain atrophy as defined by the amyloid cascade model. First, we tested a mediation model reflecting the amyloid cascade hypothesis itself, ie, Aβ42/40 → pTau181 → brain volume (model 2.0). Then, we tested 2 additional models in which MeDi score was added as a moderator either of the

**Table 2** Montreal Neurological Institute Coordinates and Statistics From Neuroimaging Analysis

$K_E$	<i>p</i> Value (FWE)	<i>p</i> Value (FDR)	TFCE	<i>p</i> Value (unc)	x z y
<b>Whole-brain results</b>					
<b>1,339</b>	0.032	0.043	2,747.53	0.001	22 -39 -14
	0.035	0.043	2,676.16	0.001	22 -32 -21
	0.036	0.043	2,670.39	0.002	22 -21 -24
<b>ROI-based results</b>					
<b>2,343</b>	0.004	0.007	841.96	<0.001	22 -38 -12
	0.006	0.007	774.82	<0.001	38 -30 -14
	0.006	0.007	772.33	<0.001	22 -21 -24
<b>1,366</b>	0.011	0.007	644.53	0.001	-20 -21 -26
	0.026	0.008	489.51	0.002	-18 -9 -12
	0.027	0.008	483.28	0.003	-30 -9 -16

Abbreviations: FDR = false discovery rate; FWE = family-wise error rate;  $K_E$  = equivalent cluster size; ROI = region of interest; TFCE = threshold free cluster enhancement value; unc = uncorrected.

path connecting  $A\beta_{42/40}$  to pTau181 (model 2.1, first-stage mediation) or of the path connecting pTau181 to brain volume (model 2.2, second-stage mediation). This analysis allows us to test whether the associations between  $A\beta_{42/40}$  and pTau181 and between pTau181 and brain volume vary at different levels of MeDi. A schematic visualization of the models is presented in figure 2.

In all models, we included age, sex, and education level as background confounds, and brain measures were also corrected for total intracranial volume. In addition, we tested the influence of *APOE*  $\epsilon 4$  as a covariate. The significance of the associations was based on confidence intervals (CIs) generated with bias corrected bootstrap with 10000 replicates. In the moderated mediation models, all predictors were mean centered. For models 2.1 and 2.2, direct and indirect effects were evaluated at different levels of the moderator (i.e., MeDi) using the mean  $\pm$  1 SD approach. In addition, we report the index of moderated mediation, which reflects whether the indirect effects vary at different levels of the moderator.

### Exploratory Analysis of MeDi Diet Components

To explore the individual contribution of each of the 9 MeDi score components, we ran additional linear regression models. Dependent variables were the memory factor score, brain volume in hippocampal and parahippocampal regions, pTau181, or  $A\beta_{42/40}$  ratio. In each model, we entered all dichotomous MeDi components at once, correcting for age, sex, education, caloric intake, BMI, and physical activity.

### Data Availability

Anonymized data generated and analyzed in the current study will be made available on reasonable request from qualified investigators.

## Results

### Brain Volume

#### Whole-Brain Results

The MeDi score showed a significant positive association with brain gray matter volume in the right parahippocampal gyrus and right hippocampus ( $p < 0.05$  FWE corrected). The opposite contrast did not show any negative association. Results are shown in figure 1A and in table 2. Figure e-1 (doi.org/10.5061/dryad.6t1g1jwxg/) shows the results corrected with the less conservative  $p < 0.05$  false discovery rate approach.

#### ROI-Based Results

Restricting the analysis to a priori ROIs revealed a bilateral association between higher MeDi and increased gray matter volume in hippocampi and parahippocampal gyri ( $p < 0.05$  FWE corrected). Of note, we observed also in this analysis a right > left asymmetry (figure 1B and table 2). The opposite contrast did not reveal any negative association. Of note, a 1-point increase in MeDi corresponds to an increase in brain volume in the significant cluster associated with  $-0.84$  years of age. The results of whole-brain and ROI-based analyses were stable correcting for caloric intake, BMI, physical activity, and *APOE*  $\epsilon 4$  status. The unthresholded T maps of whole-brain models are available at Neurovault (neurovault.org/collections/KMIELIOW/).

### Cognition

The models adjusted for age, sex, and education showed an association between MeDi and both memory ( $F_{4,507} = 57.87$ ,  $p < 0.001$ ,  $R^2 = 0.31$ ) and language ( $F_{4,507} = 59.22$ ,  $p < 0.001$ ,  $R^2 = 0.32$ ) but not for the other domains (table 3). In the models also corrected for BMI, caloric intake, and physical activity, only the association between an increased adherence

**Table 3** Associations Among MeDi Score, Cognitive Outcomes, and CSF Biomarkers

	Model	Estimate	Standard error	CI	p Value
<b>Memory</b>	1	0.05	0.02	0.01 to 0.08	0.005 <sup>a</sup>
	2	0.03	0.02	0.00 to 0.07	0.038 <sup>a</sup>
	1 + APOE	0.04	0.02	0.01 to 0.07	0.007 <sup>a</sup>
	2 + APOE	0.04	0.02	0.00 to 0.07	0.031 <sup>a</sup>
<b>Language</b>	1	0.03	0.02	0.00 to 0.06	0.027 <sup>a</sup>
	2	0.02	0.02	−0.01 to 0.05	0.261
	1 + APOE	0.03	0.02	−0.00 to 0.06	0.055
	2 + APOE	0.02	0.02	−0.01 to 0.05	0.291
<b>Executive functions</b>	1	0.01	0.02	−0.02 to 0.04	0.510
	2	0.00	0.02	−0.03 to 0.04	0.866
	1 + APOE	0.01	0.02	−0.02 to 0.04	0.561
	2 + APOE	0.00	0.02	−0.03 to 0.04	0.837
<b>Working memory</b>	1	0.02	0.02	−0.01 to 0.05	0.254
	2	0.02	0.02	−0.02 to 0.05	0.317
	1 + APOE	0.02	0.02	−0.02 to 0.05	0.327
	2 + APOE	0.02	0.02	−0.02 to 0.05	0.337
<b>Visuospatial abilities</b>	1	0.02	0.02	−0.01 to 0.05	0.241
	2	0.01	0.02	−0.02 to 0.04	0.482
	1 + APOE	0.02	0.02	−0.02 to 0.05	0.339
	2 + APOE	0.01	0.02	−0.02 to 0.04	0.543
<b>pTau181</b>	1	−2.26	0.65	−3.54 to −0.99	<0.001 <sup>a</sup>
	2	−1.96	0.68	−3.29 to −0.63	0.004 <sup>a</sup>
	1 + APOE	−1.89	0.64	−3.15 to −0.62	0.004 <sup>a</sup>
	2 + APOE	−1.64	0.67	−2.96 to −0.33	0.015 <sup>a</sup>
<b>Aβ<sub>42</sub></b>	1	24.24	12.00	0.58 to 47.90	0.045 <sup>a</sup>
	2	17.77	12.45	−6.79 to 42.33	0.155
	1 + APOE	12.58	11.54	−10.17 to 35.33	0.277
	2 + APOE	8.16	11.93	−15.36 to 31.68	0.494
<b>Aβ<sub>42/40</sub></b>	1	0.0034	0.00098	0.00 to 0.01	0.001 <sup>a</sup>
	2	0.0027	0.001	0.00 to 0.00	0.008 <sup>a</sup>
	1 + APOE	0.0022	0.0009	0.0004 to 0.0039	0.014 <sup>a</sup>

**Table 3** Associations Among MeDi Score, Cognitive Outcomes, and CSF Biomarkers (continued)

	Model	Estimate	Standard error	CI	p Value
<b>Aβ<sub>42</sub>/pTau181</b>	2 + APOE	0.0017	0.0009	−0.0001 to 0.0035	0.064
	1	0.94	0.26	0.43 to 1.45	<0.001 <sup>a</sup>
	2	0.71	0.27	0.18 to 1.24	0.009 <sup>a</sup>
	1 + APOE	0.63	0.24	0.16 to 1.09	0.009 <sup>a</sup>
	2 + APOE	0.46	0.25	−0.03 to 0.94	0.063

Abbreviations: Aβ = β-amyloid; CI = confidence interval; MeDi = Mediterranean diet; pTau181 = phosphorylated tau 181. Results of linear regression models. Covariates in model 1: age, sex, years of education. Covariates in model 2: age, sex, years of education, body mass index, total daily caloric intake, and level of physical activity. Model 1 and 2 + APOE ε4 show the results after additional correction for APOE ε4 status (carriers or noncarriers).  
<sup>a</sup> Significant.

to MeDi and an improved memory performance remained ( $F_{7,482} = 30.57$ ,  $p < 0.001$ ,  $R^2 = 0.31$ ). Here, a 1-point increase of MeDi corresponded to an increase of memory performance associated with almost −1 year of age. Correcting for APOE ε4 and time distance between baseline visit and FFQ did not change the results (table 3 and table e-7, doi.org/10.5061/dryad.6t1gljwxg/).

### CSF Biomarkers

The linear regression models showed significant associations of MeDi with pTau181 ( $F_{4,209} = 6.02$ ,  $p < 0.001$ ,  $R^2 = 0.103$ ), Aβ<sub>42/40</sub> ( $F_{4,209} = 6.15$ ,  $p < 0.001$ ,  $R^2 = 0.105$ ) and Aβ<sub>42</sub>/pTau181 ( $F_{4,209} = 6.29$ ,  $p < 0.001$ ,  $R^2 = 0.107$ ).

The associations of MeDi with pTau181 ( $F_{7,197} = 4.118$ ,  $p < 0.001$ ,  $R^2 = 0.128$ ), Aβ<sub>42/40</sub> ( $F_{7,197} = 3.509$ ,  $p = 0.0014$ ,  $R^2 = 0.111$ ), and Aβ<sub>42</sub>/pTau181 ( $F_{7,197} = 3.933$ ,  $p < 0.001$ ,  $R^2 = 0.123$ ) were stable in addition controlling for BMI, caloric intake, and physical activity (table 3). Higher adherence to MeDi showed associations with pTau181 and both Aβ<sub>42/40</sub> and Aβ<sub>42</sub>/pTau181 ratios. Specifically, in the adjusted models, a unity increase in MeDi score was associated with a decrease of 1.96 pg/mL in pTau181 and with an increase of 0.0027 and 0.71 in Aβ<sub>42/40</sub> and Aβ<sub>42</sub>/pTau181 ratios, respectively. For comparison, a 1-point increase in MeDi corresponded to a decrease of the neuropathologic burden on Aβ<sub>42/40</sub> and pTau181 associated with >−3 years of age (−3.5 and −3.33 years, respectively). Correcting for APOE ε4 reduced the associations between MeDi and CSF biomarkers for amyloid (but showing a consistent pattern of results, table 3), while the time distance between baseline visit and FFQ did not influence the results (table e-7, doi.org/10.5061/dryad.6t1gljwxg/). We observed very similar results in the analysis without outlier exclusion and using

**Table 4** Result of Mediation and Moderated-Mediation Models

	Effect	Estimate	95% Bootstrap CI	Controlling for APOE ε4 Status	
				Estimate	95% Bootstrap CI
<b>Model 1</b>	Indirect	0.017	0.007 to 0.030 <sup>a</sup>	0.016	0.006 to 0.028 <sup>a</sup>
	Direct	0.025	−0.005 to 0.056	0.024	−0.006 to 0.054
	Total	0.042	0.009 to 0.075 <sup>a</sup>	0.040	0.008 to 0.073 <sup>a</sup>
	Percent	40%		40%	
<b>Model 2.0</b>	Indirect	0.109	0.009 to 0.239 <sup>a</sup>	0.116	0.025 to 0.249 <sup>a</sup>
	Direct	0.210	−0.070 to 0.471	0.195	−0.094 to 0.473
	Total	0.319	0.071 to 0.562 <sup>a</sup>	0.311	0.048 to 0.580 <sup>a</sup>
	Percent	34%		37%	
<b>Model 2.1</b>					
<b>Below</b>	Indirect	0.133	0.011 to 0.308 <sup>a</sup>	0.142	0.030 to 0.314 <sup>a</sup>
	Percent	39%		42%	
<b>Mean</b>	Indirect	0.098	0.010 to 0.220 <sup>a</sup>	0.105	0.024 to 0.229 <sup>a</sup>
	Percent	32%		35%	
<b>Above</b>	Indirect	0.063	0.008 to 0.172 <sup>a</sup>	0.068	0.010 to 0.180 <sup>a</sup>
	Percent	23%		26%	
	IMM	−0.020	−0.065 to −0.001 <sup>a</sup>	−0.022	−0.065 to −0.001 <sup>a</sup>
<b>Model 2.2</b>					
<b>Below</b>	Indirect	0.154	0.044 to 0.292 <sup>a</sup>	0.164	0.068 to 0.306 <sup>a</sup>
	Percent	51%		54%	
<b>Mean</b>	Indirect	0.075	−0.029 to 0.205	0.083	−0.008 to 0.214
	Percent	34%		37%	
<b>Above</b>	Indirect	−0.005	−0.159 to 0.160	0.002	−0.142 to 0.160
	Percent	3%		1%	
	IMM	−0.047	−0.101 to −0.004 <sup>a</sup>	−0.048	−0.101 to −0.009 <sup>a</sup>

Abbreviations: CI = confidence interval; IMM = index moderated mediation.

Percent indicates proportion of mediated effect. Effects for the moderated mediation models are shown at different levels of the moderator. Mean: at mean level of MeDi; below and above: at −1 and +1 standard deviations from the mean of MeDi, respectively.

<sup>a</sup> Significant paths according to CIs generated with bias corrected bootstrap with 10,000 replicates.

both linear and robust linear regressions (table e-5, doi.org/10.5061/dryad.6t1g1jwxg/).

## Mediation Models

Model 1 revealed a significant indirect effect of MeDi on memory via brain volume in hippocampal and parahippocampal regions (effect estimate (est) 0.017, CI 0.007–0.03). Notably, the direct effect of MeDi on memory was no longer significant (est 0.025, CI −0.005 to 0.056), thus suggesting complete mediation. The indirect pathway representing the effect of MeDi on memory via hippocampal and parahippocampal volume accounted for 40% of the total

effect. The replication of model 1 using total gray matter volume showed a significant direct effect, while the indirect effect was weak and accounted for only 4.6% of the total effect (table e-6, doi.org/10.5061/dryad.6t1g1jwxg/).

Model 2.0 showed a complete mediation of Aβ<sub>42/40</sub> on brain volume through pTau181 in that only the indirect effect (est 0.109, CI 0.009–0.239) was significant and explained 34% of the total effect. In model 2.1, we observed a significant index of moderated mediation (est −0.02, CI −0.065 to −0.001) and significant indirect effects at all levels of the moderator. The indirect effect was larger for lower values of MeDi and



decreased for higher MeDi score. The proportion of the total effect mediated by the  $A\beta_{42/40} \rightarrow p\text{Tau181} \rightarrow \text{brain volume}$  path at different levels of MeDi was 39% at  $-1$  SD, 32% at the mean level, and 23% at  $+1$  SD. Model 2.2 showed a significant index of moderated mediation (est  $-0.047$ , CI  $-0.101$  to  $-0.004$ ) and a significant indirect effect only at the lowest level of the moderator, ie, at  $-1$  SD. Complete details are displayed in table 4. All mediation and moderated-mediation models showed consistent results when corrected for *APOE*  $\epsilon 4$  (table 4).

### Individual Contributions of MeDi Components

Table e-9 ([doi.org/10.5061/dryad.6t1g1jwxg/](https://doi.org/10.5061/dryad.6t1g1jwxg/)) displays the results of the exploratory analysis on individual MeDi components. With memory function as a dependent variable, we observed a significant positive association only for cereals ( $p = 0.013$ ). Congruently, only cereals showed a marginally significant positive association with mediotemporal volume ( $p = 0.056$ ). For both  $p\text{Tau181}$  and  $A\beta_{42/40}$  ratio, a significant association was found with the ratio of monounsaturated/saturated fat ( $p = 0.021$  and  $p = 0.038$ , respectively). Specifically, an increased ratio of monounsaturated/saturated fat was associated with increased levels of  $A\beta_{42/40}$  and decreased burden of  $p\text{Tau181}$ .

## Discussion

Overall, our results suggest that the favorable association between MeDi adherence and memory performance, found here as in many previous studies, could be mediated by preservation of brain volume in mediotemporal regions. Moreover, we show that MeDi adherence is inversely associated with both pathologic biomarkers for amyloidosis and tauopathy, which underlie AD. Finally, our data show that a healthier diet moderates the associations among  $A\beta_{42/40}$ ,  $p\text{Tau181}$ , and brain atrophy, suggesting that MeDi contributes to brain maintenance.<sup>33</sup>

First, we observed a significant association between MeDi and hippocampal and parahippocampal regions in both whole-brain and ROI-based analyses. This is in line with studies that reported positive associations between MeDi and brain morphology in cognitively normal middle- and old-aged individuals and in elderly individuals without dementia.<sup>11-15</sup> However, 1 study reported no significant association between MeDi and brain volume,<sup>34</sup> and another reported an association only with meat consumption but not with MeDi as a whole.<sup>35</sup> Compared to these studies, we analyzed a larger sample enriched for AD risk, thus possibly making our analysis more sensitive to capture brain structural variations related to MeDi. Moreover, in both negative studies, there was a larger temporal distance between dietary and MRI data assessments (5 and 9 years), which might have influenced the results. Several hypotheses could be advanced concerning the link between diet and brain structural integrity. Considering our moderated mediation results, we hypothesize that the adherence to MeDi protects brain structures from the adverse

effects of upstream pathologic events, i.e., accumulation of amyloid plaques and tau phosphorylation. This hypothesis would clarify why the association between MeDi and brain structure is specific for the mediotemporal regions: AD-related atrophy starts in these regions and colocalizes with tau accumulation.

The second main finding is the favorable association between MeDi and memory performance. In particular, we show a significant positive association between diet and a composite memory factor score, which, capitalizing on an in-depth memory assessment, was used to quantify the level of memory performance in our sample.<sup>26</sup> This finding replicates previous work performed on a smaller interim release of DELCODE<sup>36</sup> and is in agreement with the view of MeDi as a protective lifestyle factor against cognitive decline and dementia.<sup>1-3</sup> Despite a protective effect of MeDi being reported for general cognition and for different cognitive domains, memory seems to be the one that benefits more from a healthy diet,<sup>15,37,38</sup> in line with the region-specific association with brain volume. The analysis of the individual MeDi score components showed a significant association between memory and cereals. This supports previous studies showing a protective effect of cereals, in particular whole grains, on cognition.<sup>37,39</sup> We propose that the specificity of our findings for the memory domain should be interpreted in light of the mediation analysis showing that the mediotemporal volume mediates the association between MeDi and memory. Of note, the mediation effect was specific for the mediotemporal regions in that the mediating effect of total gray matter volume was very weak.

Finally, the analysis of the subsample with CSF information allowed us to investigate the associations between MeDi and AD-related biomarkers and to model their interplay with brain volume. First, we reported that MeDi is associated with lower levels of amyloid pathology as expressed by the  $A\beta_{42/40}$  ratio and with reduced  $p\text{Tau181}$ . In agreement with our observations, previous studies in middle- and old-aged, cognitively normal individuals reported that diet is associated with reduced amyloid pathology levels and amyloid accumulation as studied with <sup>11</sup>C-Pittsburgh compound B-PET assessments.<sup>17,20</sup> Of note, we observed a significant association between MeDi and  $A\beta_{42/40}$  ratio but not with  $A\beta_{42}$ . Previous studies suggested that the  $A\beta_{42/40}$  ratio is a more sensitive biomarker for AD compared to  $A\beta_{42}$ .<sup>29</sup> Moreover, a recent study on a cell culture model of AD showed the relevance  $A\beta_{42/40}$  ratio, but not total amyloid, as driver of tau pathology.<sup>40</sup> The mediation model 2.0 is in line with the amyloid cascade hypothesis, showing a link among  $A\beta_{42/40}$ ,  $p\text{Tau181}$ , and brain atrophy.<sup>32</sup> Then, in models 2.1 and 2.2, we showed that MeDi exerts a significant moderation effect both on the association between  $A\beta_{42/40}$  ratio and  $p\text{Tau181}$  and, to a lesser extent, on that between  $p\text{Tau181}$  levels and brain atrophy, specifically mitigating their associations. However, these models should be interpreted with caution because they rely on cross-sectional data and cannot therefore

prove causal pathways. A possible (and speculative) mechanistic interpretation of these observations is that MeDi acts on the triggers that connect these pathologic events, e.g., inflammation<sup>41</sup> and oxidative stress.<sup>42</sup> MeDi is indeed based on higher consumption of fruits and vegetables, whole grains, fish, and olive oil, which are known for their anti-inflammatory and antioxidant actions.<sup>43</sup> Future studies could include markers for inflammation or oxidative stress to test more fine-grained hypotheses concerning the underlying biological processes.

Notably, the exploratory analysis of the individual MeDi components showed a beneficial association between the ratio of monounsaturated/saturated fat and both pTau181 and A $\beta$ <sub>42/40</sub> ratio. Monounsaturated fats are found in many food sources such as plant oils, nuts, seeds, and animal products, and a combination of them likely accounted for the total level in our study. In Mediterranean regions, higher scores of monounsaturated/saturated fat ratio most likely reflect higher consumption of extravirgin olive, which has been associated with reduced AD pathology in mice<sup>44</sup> and with better cognitive performance in human participants in the PREDIMED trial.<sup>8</sup>

A strength of the present study is the availability of multiple data types, which enabled the integration of dietary information, cognitive data, brain morphometry, and CSF biomarkers. This allowed us to model not only the associations between MeDi and the single variables of interest but also their interplay. Another strength is that the sample is enriched for AD risk. While this constrains generalization to the older population at large, it allows studying the interaction of diet with substantial variation of amyloid, tau, and brain neurodegeneration in a group who could be a target for nutritional intervention trials. We also repeated the regression models excluding individuals with MCI, the highest-risk clinical group. This showed a stable association of MeDi with mediotemporal brain volume but not with other outcomes, pTau181, A $\beta$ <sub>42/40</sub> ratio, and memory (table e-10, doi.org/10.5061/dryad.6t1g1jwxg/). This might indicate that the beneficial associations between MeDi and AD-related biomarkers and cognition are more pronounced in the prodromal AD stages. However, these negative findings might also be attributable to reduced power in the subsample analysis and to lower variability in the outcomes.

A limitation of the present cross-sectional study is that it does not allow causal inference. However, MeDi scores are stable over years in older adults, even in the years before a diagnosis of incident dementia,<sup>1,45</sup> and Wagner et al<sup>46</sup> showed that the longitudinal trajectories of MeDi over 15 years are comparable between women who showed cognitive decline and those who did not in the Nurses' Health Study. Therefore, we posit that MeDi adherence reflects the past aggregate exposure to the MeDi ingredients, so the statistical associations with MeDi described above could result from accumulated long-term causal effects of diet. The extension to longitudinal

data, including data from DELCODE follow-ups, should be the next step to address this limitation and to validate the proposed models. Moreover, it has to be noted that the analysis of the single components presented here is exploratory and should be validated by more focused studies. Future studies in humans and animal models could focus on specific hypothesis-driven dietary components and leverage on modern techniques to directly measure their effects on the metabolome and microbiome.<sup>47</sup> Along the same line, recent efforts to map the chemical complexity of diets provide a promising avenue for a deeper understanding of the effects of diet on health and disease.<sup>48</sup> It has to be mentioned that previous studies reported an association between different dietary patterns (i.e., Western diet and the Alternative Healthy Eating Index 2010) and risk of dementia and cognitive decline<sup>49</sup> or AD-related markers such as hippocampal volume.<sup>5</sup> This might bring into question whether the results reported in our study are specific for MeDi or rather reflect a more general advantage of a healthy diet. This is linked to another limitation of our and similar studies in which MeDi adherence is defined on sample medians, thus representing the relative adherence to dietary guidelines and not the high consumption of beneficial foods in absolute terms as in Mediterranean regions. Moreover, it is possible that MeDi has systemic effects on health (e.g., modulating inflammation or cardiovascular health<sup>50</sup>) that might in turn influence AD-specific mechanisms. Our results were stable when we controlled for factors associated with cardiovascular risk (BMI, physical activity, and smoking, see table e-8, doi.org/10.5061/dryad.6t1g1jwxg/), but a deeper investigation of this topic is needed. The study of many other biomarkers such as diffusion tensor imaging, resting-state functional connectivity, and markers for neuroinflammation, especially in longitudinal study design, could help generate a more comprehensive and mechanistic understanding of the effects of MeDi on cognition in old age and early AD.

Our study supports the view of MeDi as a protective lifestyle factor against AD-related neurodegeneration and memory impairment. Longitudinal studies with AD biomarker outcomes could further examine this conjecture and pave the way for dietary interventions to delay AD.

## Acknowledgment

The authors thank all the participants of the DELCODE study for their contributions.

## Study Funding

Study funded by the German Center for Neurodegenerative Diseases (Deutsches Zentrum für Neurodegenerative Erkrankungen [DZNE]) and by the Diet Body Brain research cluster funded by the German Federal Ministry of Education and Research (grant 01EA1809C).

## Disclosure

T. Ballarini, D. Melo van Lent, J. Brunner, A. Schröder, S. Wolfgruber, S. Altenstein, F. Brosseron, K. Buerger, P.

Dechent, L. Dobisch, E. Düzel, B. Ertl-Wagner, K. Fließbach, S. Dawn Freiesleben, I. Frommann, W. Glanz, D. Hauser, J. D. Haynes, M. T. Heneka, D. Janowitz, I. Kilimann, C. Laske, F. Maier, C. D. Metzger, M. H. Munk, R. Perneczky, and O. Peters report no disclosures relevant to the manuscript; J. Priller received fees for consultation, lectures, and patents from Neurimmune, Axon, Desitin, and Epomedics. A. Ramirez, B. Rauchmann, N. Roy, K. Scheffler, A. Schneider, A. Spottke, E. J. Spruth, S. Teipel, R. Vukovich, and J. Wiltfang report no disclosures relevant to the manuscript; F. Jessen received fees for consultation from Eli Lilly, Novartis, Roche, BioGene, MSD, Piramal, Janssen, and Lundbeck. M. Wagner reports no disclosures relevant to the manuscript. Go to [Neurology.org/N](https://www.neurology.org/N) for full disclosures.

## Publication History

Received by *Neurology* August 6, 2020. Accepted in final form March 15, 2021.

## Appendix Authors

Name	Location	Contribution
<b>Tommaso Ballarini, PhD</b>	German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany	Conceptualization and design of the study; statistical analysis; interpretation of data; drafting and/or revision of manuscript for important intellectual content
<b>Debora Melo van Lent, PhD</b>	DZNE, Bonn, Germany; University of Texas Health Science Center, San Antonio	Conceptualization and design of the study; drafting and/or revision of manuscript for important intellectual content
<b>Julia Brunner, MSc</b>	DZNE, Bonn, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Alina Schröder, MSc</b>	DZNE, Bonn, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Steffen J. Wolfsgruber, PhD</b>	DZNE, Bonn, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Slawek Altenstein, Dipl-Psych</b>	DZNE, Berlin, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Frederic Brosseon, PhD</b>	DZNE, Bonn, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Katharina Buerger, MD</b>	DZNE, Munich, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Peter Dechent, PhD</b>	Georg-August-University Göttingen, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Laura Dobisch, MSc</b>	DZNE, Magdeburg, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Emrah Düzel, MD</b>	DZNE, Magdeburg, Germany	Drafting and/or revision of manuscript for important intellectual content

## Appendix (continued)

Name	Location	Contribution
<b>Birgit Ertl-Wagner, MD</b>	Ludwig-Maximilians-University, Munich, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Klaus Fließbach, MD</b>	DZNE, Bonn, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Silka Dawn Freiesleben, MSc</b>	Charité–Berlin, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Ingo Frommann, Dipl-Psych</b>	DZNE, Bonn, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Wenzel Glanz, MD</b>	DZNE, Magdeburg, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Dietmar Hauser, Dipl-Psych</b>	Charité–Berlin, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>John Dylan Haynes, PhD</b>	Bernstein Center for Computational Neuroscience, Charité–Berlin, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Michael T. Heneka, MD</b>	DZNE, Bonn, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Daniel Janowitz, MD</b>	Ludwig-Maximilians-University, Munich, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Ingo Kilimann, MD</b>	DZNE, Rostock, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Christoph Laske, MD</b>	DZNE, Tübingen, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Franziska Maier, MD</b>	University of Cologne, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Coraline Danielle Metzger, MD</b>	DZNE, Magdeburg, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Matthias H. Munk, MD</b>	DZNE, Tübingen, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Robert Perneczky, MD</b>	DZNE, Munich, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Oliver Peters, MD</b>	DZNE, Berlin, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Josef Priller, MD</b>	DZNE, Berlin, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Alfredo Ramirez, MD</b>	University of Cologne, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Boris-Stephan Rauchmann, MD</b>	Ludwig-Maximilians-University, Munich, Germany	Drafting and/or revision of manuscript for important intellectual content



## Appendix (continued)

Name	Location	Contribution
<b>Nina Roy, PhD</b>	DZNE, Bonn, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Klaus Scheffler, PhD</b>	University of Tübingen, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Anja Schneider, MD</b>	DZNE, Bonn, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Annika Spottke, MD</b>	DZNE, Bonn, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Eike Jakob Spruth, MD</b>	DZNE, Berlin, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Stefan Teipel, MD</b>	DZNE, Rostock, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Ruth Vukovich, MD</b>	University of Goettingen, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Jens Wiltfang, MD</b>	DZNE, Goettingen, Germany	Drafting and/or revision of manuscript for important intellectual content
<b>Frank Jessen, MD</b>	DZNE, Bonn, Germany	Conceptualization and design of the study; Drafting and/or revision of manuscript for important intellectual content
<b>Michael Wagner, PhD</b>	DZNE, Bonn, Germany	Conceptualization and design of the study; Interpretation of data; Drafting and/or revision of manuscript for important intellectual content

## Appendix 2 Coinvestigators

Coinvestigators are listed at [links.lww.com/WNL/B405](https://www.lww.com/WNL/B405)

## References

- Scarmeas N, Stern Y, Tang MX, Mayeux R, Luchsinger JA. Mediterranean diet and risk for Alzheimer's disease. *Ann Neurol*. 2006;59(6):912-921.
- Lourida I, Soni M, Thompson-Coon J, et al. Mediterranean diet, cognitive function, and dementia: a systematic review. *Epidemiology*. 2013;24(4):479-489.
- Petersson SD, Philippou E. Mediterranean diet, cognitive function, and dementia: a systematic review of the evidence. *Adv Nutr*. 2016;7(5):889-904.
- Sofi F, Cesari F, Abbate R, Franco Gensini G, Casini A. Adherence to Mediterranean diet and health status: meta-analysis. *BMJ*. 2008;337:a1344.
- Akbaraly T, Sexton C, Zsoldos E, et al. Association of long-term diet quality with hippocampal volume: longitudinal cohort study. *Am J Med*. 2018;131(11):1372-1381.e4.
- Psaltopoulou T, Kyzrois A, Stathopoulos P, Trichopoulos D, Vassilopoulos D, Trichopoulos A. Diet, physical activity and cognitive impairment among elders: the EPIC-Greece cohort (European Prospective Investigation Into Cancer and Nutrition). *Public Health Nutr*. 2008;11(10):1054-1062.
- Valls-Pedret C, Sala-Vila A, Serra-Mir M, et al. Mediterranean diet and age-related cognitive decline: a randomized clinical trial. *JAMA Intern Med*. 2015;175(7):1094-1103.
- Martínez-Lapiscina EH, Clavero P, Toledo E, et al. Virgin olive oil supplementation and long-term cognition: the PREDIMED-NAVARRA randomized, trial. *J Nutr Health Aging*. 2013;17(6):544-552.
- Singh B, Parsaik AK, Mielke MM, et al. Association of Mediterranean diet with mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis. *J Alzheimers Dis*. 2014;39(2):271-282.
- Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA. Mediterranean diet and mild cognitive impairment. *Arch Neurol*. 2009;66(2):216-225.
- Matthews DC, Davies M, Murray J, et al. Physical activity, Mediterranean diet and biomarkers-assessed risk of Alzheimer's: a multi-modality brain imaging study. *Adv J Mol Imaging*. 2014;4(4):43-57.
- Mosconi L, Murray J, Tsui WH, et al. Mediterranean diet and magnetic resonance imaging-assessed brain atrophy in cognitively normal individuals at risk for Alzheimer's disease. *J Prev Alzheimers Dis*. 2014;1(1):23-32.
- Staubo SC, Aakre JA, Vemuri P, et al. Mediterranean diet, micronutrients and macronutrients, and MRI measures of cortical thickness. *Alzheimers Dement*. 2017;13(2):168-177.
- Gu Y, Brickman AM, Stern Y, et al. Mediterranean diet and brain structure in a multiethnic elderly cohort. *Neurology*. 2015;85(20):1744-1751.
- Karstens AJ, Tussing-Humphreys L, Zhan L, et al. Associations of the Mediterranean diet with cognitive and neuroimaging phenotypes of dementia in healthy older adults. *Am J Clin Nutr*. 2019;109(2):361-368.
- Vassilaki M, Aakre JA, Syrjänen JA, et al. Mediterranean diet, its components, and amyloid imaging biomarkers. *J Alzheimers Dis*. 2018;64(1):281-290.
- Berti V, Walters M, Sterling J, et al. Mediterranean diet and 3-year Alzheimer brain biomarker changes in middle-aged adults. *Neurology*. 2018;90(20):e1789-e1798.
- Hill E, Szoek C, Dennerstein L, Campbell S, Clifton P. Adherence to the Mediterranean diet is not related to beta-amyloid deposition: data from the Women's Healthy Ageing Project. *J Prev Alzheimers Dis*. 2018;5(4):137-141.
- Merrill DA, Siddarth P, Raji CA, et al. Modifiable risk factors and brain positron emission tomography measures of amyloid and tau in nondemented adults with memory complaints. *Am J Geriatr Psychiatry*. 2016;24(9):729-737.
- Rainey-Smith SR, Gu Y, Gardener SL, et al. Mediterranean diet adherence and rate of cerebral Aβ-amyloid accumulation: data from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. *Transl Psychiatry*. 2018;8(1):238.
- Jessen F, Spottke A, Boecker H, et al. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE). *Alzheimers Res Ther*. 2018;10(1):15.
- Jessen F, Amariglio RE, van Bostel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. *Alzheimers Dement*. 2014;10(6):844-852.
- Molineuvo JL, Rabin LA, Amariglio R, et al. Implementation of subjective cognitive decline criteria in research studies. *Alzheimers Dement*. 2017;13(3):296-311.
- Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7(3):270-279.
- Washburn RA, Smith KW, Jette AM, Janney CA. The Physical Activity Scale for the Elderly (PASE): development and evaluation. *J Clin Epidemiol*. 1993;46(2):153-162.
- Wolfgruber S, Kleindem L, Gusk J, et al. Minor neuropsychological deficits in patients with subjective cognitive decline. *Neurology*. 2020;95(9):e1134-e1143.
- Noethlings U, Hoffmann K, Bergmann MM, Boeing H. Portion size adds limited information on variance in food intake of participants in the EPIC-Potsdam study. *J Nutr*. 2003;133(2):510-515.
- Trichopoulos A, Costacou T, Bamia C, Trichopoulos D. Adherence to a Mediterranean diet and survival in a Greek population. *N Engl J Med*. 2003;348(26):2599-2608.
- Wiltfang J, Esselmann H, Bibl M, et al. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-tau in patients with low- and high-CSF A beta 40 load. *J Neurochem*. 2007;101(4):1053-1059.
- Ashburner J, Friston KJ. Voxel-based morphometry: the methods. *Neuroimage*. 2000;11(6):805-821.
- Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. *Neurobiol Aging*. 1995;16(3):271-278.
- Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol Med*. 2016;8(6):595-608.
- Stern Y, Arenaza-Urquijo EM, Bartrés-Faz D, et al. Whitepaper: defining and investigating cognitive reserve, brain reserve, and brain maintenance. *Alzheimers Dement*. 2020;16(9):1305-1311.
- Pelletier A, Barul C, Féart C, et al. Mediterranean diet and preserved brain structural connectivity in older subjects. *Alzheimers Dement*. 2015;11(9):1023-1031.
- Titova OE, Ax E, Brooks SJ, et al. Mediterranean diet habits in older individuals: associations with cognitive functioning and brain volumes. *Exp Gerontol*. 2013;48(12):1443-1448.
- Wesselman LMP, Melo van Lent D, Schröder A, et al. Dietary patterns are related to cognitive functioning in elderly enriched with individuals at increased risk for Alzheimer's disease. *Eur J Nutr*. 2021;60(2):849-860.
- Anastasiou CA, Yannakoulia M, Kosmidis MH, et al. Mediterranean diet and cognitive health: initial results from the Hellenic Longitudinal Investigation of Ageing and Diet. *PLoS One*. 2017;12(8):e0182048.
- Loughrey DG, Lavecchia S, Brennan S, Lawlor BA, Kelly ME. The impact of the Mediterranean diet on the cognitive functioning of healthy older adults: a systematic review and meta-analysis. *Adv Nutr*. 2017;8(4):571-586.
- Samieri C, Grodstein F, Rosner BA, et al. Mediterranean diet and cognitive function in older age. *Epidemiology*. 2013;24(4):490-499.



40. Su Kwak S, Washicosky KJ, Brand E, et al. Amyloid- $\beta$ 42/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimer's disease. *Nat Commun.* 2020; 11(1):1-14.
41. Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer's disease. *Alzheimers Dement.* 2018;4: 575-590.
42. Tosti V, Bertozzi B, Fontana L. Health benefits of the Mediterranean diet: metabolic and molecular mechanisms. *J Gerontol A Biol Sci Med Sci.* 2018;73(3):318-326.
43. Tönnies E, Trushina E. Oxidative stress, synaptic dysfunction, and Alzheimer's disease. *J Alzheimers Dis.* 2017;57(4):1105-1121.
44. Qosa H, Mohamed LA, Batareseh YS, et al. Extra-virgin olive oil attenuates amyloid- $\beta$  and tau pathologies in the brains of TgSwDI mice. *J Nutr Biochem.* 2015;26(12):1479-1490.
45. Scarmeas N, Luchsinger JA, Schupf N, et al. Physical activity, diet, and risk of Alzheimer disease. *JAMA.* 2009;302(6):627-637.
46. Wagner M, Grodstein F, Proust-Lima C, Samieri C. Long-term trajectories of body weight, diet, and physical activity from midlife through late life and subsequent cognitive decline in women. *Am J Epidemiol.* 2020;189(4):305-313.
47. Jin Q, Black A, Kales SN, Vatter D, Ruiz-Canela M, Sotos-Prieto M. Metabolomics and microbiomes as potential tools to evaluate the effects of the Mediterranean diet. *Nutrients.* 2019;11(1):207.
48. Barabási AL, Menichetti G, Joseph L. The unmapped chemical complexity of our diet. *Nat Food.* 2020;1:33-37.
49. van de Rest O, Am Berendsen A, Haveman-Nies A, de Groot LC. Dietary patterns, cognitive decline, and dementia: a systematic review. *Adv Nutr.* 2015;6(2):154-168.
50. Dinu M, Pagliai G, Casini A, Sofi F. Mediterranean diet and multiple health outcomes: an umbrella review of meta-analyses of observational studies and randomised trials. *Eur J Clin Nutr.* 2018;72(1):30-43.

# Neurology®

## Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age

Tommaso Ballarini, Debora Melo van Lent, Julia Brunner, et al.

*Neurology* 2021;96:e2920-e2932 Published Online before print May 5, 2021

DOI 10.1212/WNL.0000000000012067

**This information is current as of May 5, 2021**

<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://n.neurology.org/content/96/24/e2920.full">http://n.neurology.org/content/96/24/e2920.full</a>
<b>References</b>	This article cites 50 articles, 9 of which you can access for free at: <a href="http://n.neurology.org/content/96/24/e2920.full#ref-list-1">http://n.neurology.org/content/96/24/e2920.full#ref-list-1</a>
<b>Citations</b>	This article has been cited by 2 HighWire-hosted articles: <a href="http://n.neurology.org/content/96/24/e2920.full##otherarticles">http://n.neurology.org/content/96/24/e2920.full##otherarticles</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>Alzheimer's disease</b> <a href="http://n.neurology.org/cgi/collection/alzheimers_disease">http://n.neurology.org/cgi/collection/alzheimers_disease</a> <b>Memory</b> <a href="http://n.neurology.org/cgi/collection/memory">http://n.neurology.org/cgi/collection/memory</a> <b>MRI</b> <a href="http://n.neurology.org/cgi/collection/mri">http://n.neurology.org/cgi/collection/mri</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2021 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

